香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 PegBio Co., Ltd. 派格生物醫藥（杭州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2565） 自願性公告 派格生物與騰瑞製藥達成派達康中國大陸獨家商業化合作 商業化目標累計銷售規模超過人民幣100億元並獲得約1.4億港幣權益金 本公告乃派格生物醫藥（杭州）股份有限公司（「本公司」）自願作出，以使本公司股 東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）欣然宣佈，近日與上海騰瑞製藥股份有限公 司（「騰瑞製藥」）就本公司核心產品派達康（「目標產品」）在中國大陸地區的商業 化合作簽署戰略合作協議。根據合作安排，雙方將整合各自在研發及商業化方面 的資源優勢，共同推進目標產品在中國大陸地區的市場推廣與商業化佈局。本次 合作標誌著公司核心產品商業化進程邁入新的階段。 根據合作協議的商業化規劃，雙方將依託騰瑞製藥覆蓋全國的商業化網絡與學術 推廣能 ...

Core Viewpoint - Jichuan Pharmaceutical has signed an exclusive commercialization rights agreement with Kangfang Biopharmaceutical, allowing Jichuan to commercialize the PCSK9 monoclonal antibody drug, Inusimab injection, in China [1] Group 1: Agreement Details - Jichuan Pharmaceutical's wholly-owned subsidiary will pay a total of 80 million yuan (including tax) as an authorization fee to Kangfang [1] - Additionally, Jichuan will pay up to 10 million yuan (including tax) in milestone payments [1] Group 2: Product Information - Inusimab injection is an innovative drug developed by Kangfang, primarily used for treating primary hypercholesterolemia and mixed hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) [1] - The drug works by specifically binding to PCSK9 and blocking its interaction with low-density lipoprotein receptors (LDL-R), thereby restoring LDL-R expression levels to enhance the clearance of low-density lipoprotein cholesterol (LDL-C) from plasma [1] Group 3: Strategic Implications - The completion of this transaction is expected to enrich the product line of Jichuan Pharmaceutical, contributing to the sustainable development of the company's business [1]

Core Viewpoint - Zhejiang Xianju Pharmaceutical Co., Ltd. has signed a tripartite agreement with Hangzhou Aomei Pharmaceutical Co., Ltd. and Aspen (Guang Dong) Pharmaceutical Co., Ltd. for the exclusive marketing of the drug Agerglucoside Sodium Injection in mainland China, indicating a strategic move towards commercialization of the product [1][2][12]. Group 1: Agreement Details - The tripartite agreement allows Aspen to act as the exclusive marketing service provider for Agerglucoside Sodium Injection in mainland China, excluding Hong Kong, Macau, and Taiwan [2][8]. - The commercialization milestone sharing agreement stipulates a 50% split of milestone payments and net sales revenue between Xianju Pharmaceutical and Aomei Pharmaceutical after deducting relevant costs [2][10]. - Additional agreements include a raw material supply agreement and a contract for commissioned production of Agerglucoside Sodium Injection, ensuring a stable supply and quality assurance for the product [3][10]. Group 2: Company Background - Hangzhou Aomei Pharmaceutical Co., Ltd. was established on October 25, 2000, with a registered capital of 69.825291 million RMB, focusing on medical research, chemical product sales, and drug production [4][5]. - Aspen (Guang Dong) Pharmaceutical Co., Ltd. was founded on January 31, 1997, with a registered capital of 57.6 million USD, specializing in the wholesale and production of various pharmaceutical products [5][6]. Group 3: Impact on Company - The signing of these agreements is a preparatory step for the future commercialization of Agerglucoside Sodium Injection, leveraging Aspen's extensive market experience in the anesthesia field to enhance product promotion and sales [12]. - The agreements clarify the revenue distribution and supply assurance mechanisms for the product post-approval, which is beneficial for the product's market entry and aligns with the interests of the company and its shareholders [12][13].

Core Viewpoint - Green Leaf Pharmaceutical (02186.HK) has signed a cooperation agreement with Jiangsu Enhua Pharmaceutical Co., Ltd. and its subsidiary, Jiangsu Enhua and Xin Medical Marketing Co., Ltd., granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [1] Group 1 - The three products involved are Risperidone microspheres (Riketu), Paliperidone palmitate injection (Ruibailai), and Paliperidone palmitate injection (Meibiri), all of which are used for the treatment of schizophrenia [1] - Enhua will be responsible for the exclusive distribution and commercialization of these products in mainland China, while the group retains ownership of the assets, registration certificates, and all intellectual property rights related to the products [1] - The agreement is set for a duration of ten years, and Enhua will make a one-time non-refundable payment of $20 million as a licensing fee to the group [1]